$8.84
0.242.79%
At Close: -
$8.84
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Fulcrum Therapeutics
FULCNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Fulcrum Therapeutics (NASDAQ:FULC) Stock, Analyst Ratings, Price Targets, Forecasts
Fulcrum Therapeutics Inc has a consensus price target of $14.58 based on the ratings of 12 analysts. The high is $37 issued by SVB Leerink on August 13, 2021. The low is $6 issued by Goldman Sachs on January 26, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Cantor Fitzgerald, and HC Wainwright & Co. on July 10, 2024, May 20, 2024, and May 14, 2024, respectively. With an average price target of $21 between Cantor Fitzgerald, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 137.56% upside for Fulcrum Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
Goldman Sachs
Oppenheimer
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Fulcrum Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 160.18% | Cantor Fitzgerald | Kristen Kluska | $23 → $23 | Reiterates | Overweight → Overweight | Get Alert |
| 05/20/2024 | Buy Now | 160.18% | Cantor Fitzgerald | Kristen Kluska | → $23 | Initiates | → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 92.31% | HC Wainwright & Co. | Andrew Fein | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 69.68% | Goldman Sachs | Corinne Jenkins | $6 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 05/14/2024 | Buy Now | 58.37% | Oppenheimer | Matthew Biegler | $16 → $14 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | 69.68% | Goldman Sachs | Corinne Jenkins | → $15 | Upgrade | Neutral → Buy | Get Alert |
| 03/13/2024 | Buy Now | 58.37% | RBC Capital | Gregory Renza | → $14 | Initiates | → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 92.31% | HC Wainwright & Co. | Andrew Fein | $14 → $17 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 69.68% | Piper Sandler | Edward Tenthoff | $13 → $15 | Maintains | Overweight | Get Alert |
| 01/26/2024 | Buy Now | -32.13% | Goldman Sachs | Madhu Kumar | $5 → $6 | Maintains | Neutral | Get Alert |
| 01/25/2024 | Buy Now | -32.13% | Goldman Sachs | Madhu Kumar | $5 → $6 | Maintains | Neutral | Get Alert |
| 09/25/2023 | Buy Now | -43.44% | Goldman Sachs | Madhu Kumar | → $5 | Initiates | → Neutral | Get Alert |
| 08/23/2023 | Buy Now | 58.37% | HC Wainwright & Co. | Andrew Fein | $5 → $14 | Upgrade | Neutral → Buy | Get Alert |
| 08/22/2023 | Buy Now | 81% | Oppenheimer | Matthew Biegler | → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | Buy Now | 24.43% | Stifel | Dae Gon Ha | → $11 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2023 | Buy Now | -43.44% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/16/2023 | Buy Now | 81% | Oppenheimer | Matthew Biegler | $20 → $16 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | -43.44% | HC Wainwright & Co. | Andrew Fein | $6 → $5 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | -66.06% | Goldman Sachs | Madhu Kumar | $9 → $3 | Maintains | Neutral | Get Alert |
| 05/04/2023 | Buy Now | -66.06% | Goldman Sachs | Madhu Kumar | $9 → $3 | Downgrade | Buy → Neutral | Get Alert |
| 03/13/2023 | Buy Now | 1.81% | Goldman Sachs | Madhu Kumar | $17 → $9 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | -20.81% | Morgan Stanley | Matthew Korn | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 03/10/2023 | Buy Now | -32.13% | HC Wainwright & Co. | Andrew Fein | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/10/2023 | Buy Now | -9.5% | Credit Suisse | Judah Frommer | $11 → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 02/28/2023 | Buy Now | 126.24% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -9.5% | Morgan Stanley | Matthew Harrison | $27 → $8 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/27/2023 | Buy Now | 126.24% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 126.24% | Oppenheimer | Matthew Biegler | $26 → $20 | Maintains | Outperform | Get Alert |
| 02/27/2023 | Buy Now | 24.43% | Credit Suisse | Judah Frommer | $19 → $11 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 205.43% | Morgan Stanley | Matthew Harrison | $26 → $27 | Maintains | Overweight | Get Alert |
| 01/23/2023 | Buy Now | 137.56% | Piper Sandler | Edward Tenthoff | $18 → $21 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | 92.31% | Goldman Sachs | Madhu Kumar | $11 → $17 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 24.43% | Goldman Sachs | Madhu Kumar | → $11 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 194.12% | Morgan Stanley | Matthew Harrison | $25 → $26 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 114.93% | Credit Suisse | Judah Frommer | $22 → $19 | Maintains | Outperform | Get Alert |
| 06/13/2022 | Buy Now | 126.24% | HC Wainwright & Co. | Andrew Fein | $40 → $20 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 182.81% | Morgan Stanley | Matthew Harrison | $26 → $25 | Maintains | Overweight | Get Alert |
| 04/12/2022 | Buy Now | 194.12% | Morgan Stanley | Matthew Harrison | $25 → $26 | Maintains | Overweight | Get Alert |
| 03/25/2022 | Buy Now | 295.93% | Credit Suisse | Judah Frommer | $30 → $35 | Maintains | Outperform | Get Alert |
| 03/08/2022 | Buy Now | 273.3% | Oppenheimer | Matthew Biegler | → $33 | Initiates | → Outperform | Get Alert |
| 08/17/2021 | Buy Now | 352.49% | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
| 08/13/2021 | Buy Now | 318.55% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 08/11/2021 | Buy Now | 239.37% | Credit Suisse | Judah Frommer | — | Maintains | Outperform | Get Alert |
| 08/11/2021 | Buy Now | 284.62% | Morgan Stanley | Matthew Harrison | — | Upgrade | Equal-Weight → Overweight | Get Alert |
FAQ
What is the target price for Fulcrum Therapeutics (FULC) stock?
The latest price target for Fulcrum Therapeutics (NASDAQ:FULC) was reported by Cantor Fitzgerald on July 10, 2024. The analyst firm set a price target for $23.00 expecting FULC to rise to within 12 months (a possible 160.18% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
The latest analyst rating for Fulcrum Therapeutics (NASDAQ:FULC) was provided by Cantor Fitzgerald, and Fulcrum Therapeutics reiterated their overweight rating.
When was the last upgrade for Fulcrum Therapeutics (FULC)?
The last upgrade for Fulcrum Therapeutics Inc happened on May 14, 2024 when Goldman Sachs raised their price target to $15. Goldman Sachs previously had a neutral for Fulcrum Therapeutics Inc.
When was the last downgrade for Fulcrum Therapeutics (FULC)?
The last downgrade for Fulcrum Therapeutics Inc happened on May 4, 2023 when Goldman Sachs changed their price target from $9 to $3 for Fulcrum Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a reiterated with a price target of $23.00 to $23.00. The current price Fulcrum Therapeutics (FULC) is trading at is $8.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.